FDA Expands Indication of Vyvgart (Efgartigimod Alfa) for Adults With Seronegative Myasthenia Gravis by Madaline Spencer| Published on: May 12, 2026

https://checkrare.com/fda-expands-indication-of-vyvgart-efgartigimod-alfa-for-adults-with-seronegative-myasthenia-gravis/ The US Food and Drug Administration (FDA) has approved Vyvgart (efgartigimod alfa) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) for the treatment of adult patients who have anti-MuSK-Ab positive, anti-LRP4-Ab positive, and/or triple seronegative generalized myasthenia gravis (gMG). The medication was previously approved to treat patients with anti-AChR-Ab positive gMG.